JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

JNJ

237.25

+0.8%↑

UNH

268

-3.16%↓

TMO

549.47

-3.13%↓

ABT

108.73

-0.65%↓

ISRG

478.55

-0.02%↓

Strona główna・Stock List・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Open

SectorHealthcare

1.26 5

Buy Sell

Overview

Share price change

24h

Current

Min

1.23

Max

1.38

Key metrics
By Trading Economics
Income	-16M -13M
Sales	-15M 14M
Profit margin	-90.037
Employees	103
EBITDA	-16M -10M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+214.84% upside

Dividends
By Dow Jones
Next Earnings	5 mar 2026

Market Stats
By TradingEconomics
Market Cap	-40M 454M
Previous open	-3.74
Previous close	1.26

News Sentiment

By Acuity

15%

85%

15 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

0.6863 / 0.72 Support & Resistance

Lexicon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 lut 2026, 00:00 UTC

Hot Stocks

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 lut 2026, 22:55 UTC

Earnings

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 lut 2026, 21:44 UTC

Earnings

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 lut 2026, 21:39 UTC

Earnings

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 lut 2026, 00:00 UTC

Earnings

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 lut 2026, 00:00 UTC

Earnings

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 lut 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 lut 2026, 23:45 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 lut 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 lut 2026, 22:59 UTC

Acquisitions, Mergers, Takeovers

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 lut 2026, 22:30 UTC

Earnings

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 lut 2026, 22:30 UTC

Earnings

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 lut 2026, 22:21 UTC

Earnings

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 lut 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 lut 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 lut 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4 lut 2026, 21:53 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 lut 2026, 21:51 UTC

Earnings

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 lut 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

4 lut 2026, 21:50 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

4 lut 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 lut 2026, 21:45 UTC

Earnings

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 lut 2026, 21:44 UTC

Earnings

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 lut 2026, 21:43 UTC

Earnings

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 lut 2026, 21:41 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 lut 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 lut 2026, 21:30 UTC

Earnings

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 lut 2026, 21:30 UTC

Earnings

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 lut 2026, 21:30 UTC

Earnings

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

214.84% upside

12 Months Forecast

Average 4.03 USD 214.84%

High 6 USD

Low 2.1 USD

Based on 3 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Lexicon Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.6863 / 0.72Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

15 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.